Chandan Healthcare Limited — Investor Meet, 20-11-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Chandan Healthcare reported strong H1 FY26 financial results, with total sales reaching Rs. 137.49 Cr (+23.38%) and PAT at Rs. 15.6 Cr (+46.59%). EBITDA margin expanded to 21.81%, with diagnostic business EBITDA at 34.22%. The company is expanding rapidly, opening six new diagnostic centers in H1 and targeting 100 new labs plus 1,000 franchise collection points across 17 states. A key 5-year partnership with Jeena Sikho is expected to drive significant revenue from next quarter, utilizing these new labs. Management anticipates sustained 20-25% annual profit growth, aiming for a 35% diagnostic EBITDA margin by FY26. A Rs. 104 Cr preferential share issue will fund this aggressive expansion. Sentiment remains confident in future growth.